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Protocol
AbstrACt
Introduction While breast cancer outcomes are improving 
steadily in younger women due to advances in screening 
and improved therapies, there has been little change in 
outcomes among the older age group. It is inevitable that 
comorbidities/frailty rates are higher, which may increase 
the risks of some breast cancer treatments such as surgery 
and chemotherapy, many older women are healthy and 
may beneit from their use. Adjusting treatment regimens 
appropriately for age/comorbidity/frailty is variable and 
largely non-evidence based, speciically with regard to rates 
of surgery for operable oestrogen receptor-positive disease 
and rates of chemotherapy for high-risk disease.
Methods and analysis This multicentre, parallel group, 
pragmatic cluster randomised controlled trial (RCT) (2015-
18) reported here is nested within a larger ongoing ‘Age 
Gap Cohort Study’ (2012-18RP-PG-1209-10071), aims 
to evaluate the effectiveness of a complex intervention of 
decision support interventions to assist in the treatment 
decision making for early breast cancer in older women. 
The interventions include two patient decision aids 
(primary endocrine therapy vs surgery/antioestrogen 
therapy and chemotherapy vs no chemotherapy) and a 
clinical treatment outcomes algorithm for clinicians.
Ethics and dissemination National and local ethics 
committee approval was obtained for all UK participating 
sites. Results from the trial will be submitted for publication in 
international peer-reviewed scientiic journals.
IrAs reference 115550.
trial registration number European Union Drug 
Regulating Authorities Clinical Trials (EudraCT) number 
2015-004220-61;Pre-results. Sponsor's Protocol Code 
Number Shefield Teaching Hospitals STH17086. ISRCTN 
32447*.
* The wider Age Gap study commenced as a cohort study 
in 2012/2013, collecting prospective observational data 
on older women. At the time there was no requirement 
IntroduCtIon
Background and rationale
Breast cancer is the most common cancer in 
for registration on the ISRCTN database as the trial was 
approved prior to 2013 and was only a cohort study, 
therefore the study team made public notification via the 
Cancer help database and more recently registered it on 
the EURDRACT database last year. The trial protocol was 
changed late 2015/2016 to convert the study to a clus-
ter RCT and at that point registered the revised protocol 
with the ISRCTN.
strengths and limitations of this study
 ► The two evidence-based decision support 
interventions (DESIs) for women over 70 years 
diagnosed with breast cancer who are offered a 
choice of primary endocrine therapy or surgery 
(plus adjuvant endocrine therapy, hereafter 
termed surgery/AET,  antioestrogen therapy) or 
chemotherapy versus no chemotherapy are, to the 
best of our knowledge, the irst of its kind worldwide.
 ► The web-based clinical outcomes management 
algorithm is the irst of its kind and allows patient 
age, comorbidities, frailty and cancer characteristics 
to be considered in predicting breast cancer survival 
and cancer outcomes.
 ► A limitation of the trial will potentially be selection 
bias from recruitment and poor uptake/utilisation of 
the DESIs at intervention sites.
 ► A second limitation may be an inability to 
demonstrate a beneit in terms of cancer survival 
rates without at least 5–10 years follow-up or an 
overall survival advantage due to the competing 
causes of death in this age group.
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women in the UK, with over 53 000 new cases being diag-
nosed in the UK each year.1 Of these, 16 000 women will 
be over the age of 70, a figure which is rising steadily as 
the UK population ages.2 While breast cancer outcomes 
are improving steadily in younger women due to advances 
in screening and improved therapies, there has been little 
change in outcomes in this older age group of women. 
The UK lags significantly behind other European coun-
tries in its outcomes for these women. There is a wide 
variation in practice in the management of breast cancer 
in older women.3 The gold standard of care for early 
breast cancer is surgical removal of the primary cancer 
(mastectomy or conservation surgery), and diagnostic 
or therapeutic axillary nodal surgery followed by stage 
and immunophenotype appropriate adjuvant therapies 
(chemotherapy, trastuzumab, antioestrogens and radio-
therapy) to reduce the risks of disease recurrence. There 
is consistent evidence that older women are less likely to 
receive surgery, chemotherapy, radiotherapy and trastu-
zumab, based on the premise that there is less evidence 
of efficacy and a greater risk of treatment morbidity.4 In 
the case of surgery, up to 40% of older women do not 
undergo surgery for their breast cancer, and their treat-
ment is mainly with antioestrogen tablets alone, known as 
primary endocrine therapy (PET).5 While it is inevitable 
that in older women, comorbidities and frailty rates are 
higher, and which will increase the risks of some breast 
cancer treatments, such as surgery and chemotherapy, 
many older women are healthy and will benefit in terms 
of breast cancer outcomes from their use. Selection of 
appropriate age, comorbidity and frailty-adjusted treat-
ment regimens is highly variable, largely non-evidence 
based and often fails to adequately consider the needs or 
wishes of patients. Two key areas of local practice varia-
tion are rates of surgery for operable oestrogen receptor 
(ER) positive disease and rates of chemotherapy for high-
risk disease. PET rates vary fourfold between UK centres3 
and are not accounted for by case mix adjustment. Simi-
larly, rates of chemotherapy vary 10-fold.4
Recent reports have advocated the use of PET only in 
the very old or frail.6 Current national guidelines state 
that patients with operable breast cancer should be 
treated with surgery, and not PET, ‘irrespective of age’ 
unless this is precluded by comorbidities7; while the Inter-
national Society of Geriatric Oncology and European 
Society of Breast Cancer Specialists recommend that PET 
should only be offered to patients with a ‘short estimated 
life expectancy (less than 2 to 3 years), who are consid-
ered unfit for surgery… or who refuse surgery.’8 However, 
as a large number of older women are treated with PET 
in UK and other countries, it is not clear whether this 
guidance is being followed consistently. PET is asso-
ciated with high rates of patient satisfaction and low 
treatment morbidity but in the medium and long term 
some women may need a change of therapy once antio-
estrogen resistance develops.9 Randomised trials and a 
recent Cochrane review have shown that surgery (plus 
adjuvant antioestrogens hereinafter termed surgery/
AET, antioestrogen therapy) and PET have equivalent 
overall survival rates.10 11 However, for fitter women with 
a longer predicted life expectancy, there is evidence that 
breast cancer specific survival rates are inferior with PET.12 
For very frail women where surgery would be unsafe or 
poorly tolerated, PET is the clear choice in women with 
oestrogen-sensitive disease.12
For women at intermediate or higher risk of surgery 
complications, there is a complex series of trade-offs to 
be made for each patient. The decision must balance 
the risks of surgical morbidity (pain, risks associated with 
hospitalisation, surgical complications) but with a greater 
certainty of local disease control, against the minimal 
morbidity with PET but a risk of later local disease 
progression and the need for a change of treatment to 
either surgery or alternate AET.13–15
Chemotherapy utilisation is also very low in women 
over 70 (14%)4 and almost non-existent in women over 
80, even in those where high phenotypic risk is present 
(high grade, node positive, ER negative, HER2 positive).4 
Rates of chemotherapy can vary widely between UK breast 
units, between 6% and 60% in high-risk women.16 This 
reflects the fact that most of the randomised trials have 
upper age cut-offs at age 70 or recruit very poorly in this 
age group, meaning there is little evidence of whether 
it is effective or not. In addition, there is evidence of an 
increased risk of significant complications such as neutro-
penic sepsis in older women.17 This clearly suggests that 
guidelines for best practice are required. The primary 
tool used by oncologists to determine the likely benefit 
of chemotherapy on a patient level basis is Adjuvant!On-
line,18although this has been shown to be inaccurate in 
older women.19 The more recently developed PREDICT 
tool20 performs better in this age group but has limited 
functionality for taking comorbidity and frailty into 
account.
This cluster randomised trial will evaluate the 
implementation of two (‘complex’) decision support 
interventions (DESIs) designed to be used by both clini-
cians and patients to assist in the decision making about 
treatment for early breast cancer in older women.
the bridging the Age Gap study
The Bridging the Age Gap study21 is an NIHR (National 
Institute for Health Research) funded programme of 
research (2012-18RP-PG-1209-10071) examining breast 
cancer management in older women with the ultimate 
aim of improving outcomes by providing high-quality 
evidence to support treatment decision making in this 
age group.
The study protocol reported here focuses exclu-
sively on the cluster randomised trial part of the wider 
Bridging the Age Gap study.21 The study group has devel-
oped two patient-facing DESIs based on a systematic 
evidence summary, expert reference group consultation, 
patient interviews22–24 and questionnaires about infor-
mational needs and preferences and extensive user and 
field testing with both healthy older women and older 
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women who had faced the decision relating to the choice 
of surgery/AET or PET in frailer women with ER-positive 
breast cancer, and the decision regarding use of adjuvant 
chemotherapy in fitter women with high-risk cancers. 
Each DESI includes a clinician-facing clinical manage-
ment algorithm and two patient-facing decision aids 
(PtDAs). The clinician-facing management algorithms 
derive from detailed cancer registry outcome data linked 
to treatment-related morbidity and patient and cancer 
characteristics from the UK cancer registry (2002–2010) 
for two UK regions (Northern and Yorkshire and East 
Midlands) which are representatives of the UK population 
as a whole in terms of demography, population structure 
and deprivation. This is a large diverse area, representing 
23% of the UK population.25 These online algorithms 
allow patient age, comorbidities, frailty and cancer char-
acteristics to be considered by a clinician in predicting 
survival and cancer outcomes and to help inform breast 
cancer management decisions for older women.25 The 
PtDAs are in the form of a booklet and a (brief) option 
grid for the clinical decision in question.26 27
The trial will evaluate these tools in a cluster randomised 
trial across 53 UK breast units according to the study sche-
matic (figure 1).
The aim of this trial is to evaluate if, how and to what 
extent, the use of the DESIs embedded as ‘standard of 
care’ within intervention arm sites improves quality of life 
(QoL), decision quality (integrating knowledge, attitudes 
and decision made), coping and illness representations, 
and reduces decision regret, thus indicating improved 
informed decision making of older women about treat-
ment options for their breast cancer.
To our knowledge, this is the first randomised 
controlled trial (RCT) to have been undertaken to 
explore this issue.
objectives
The objectives are:
1. To assess the effectiveness of the implementation of 
DESIs26 27 in clinical practice in terms of improving 
patient QoL, decision quality (integrating 
knowledge, attitudes and decision made), coping 
and illness representations, and reducing decision 
regret, thus indicating improved informed decision 
making.
2. To determine if how, or to what extent, the clinical 
outcomes management algorithm impacts on clinical 
decision making among clinicians (change in PET/
surgery rates and chemotherapy rates).
3. To determine whether the DESIs are effective in 
improving short, medium and long-term cancer 
outcomes in this age group of women (treatment 
morbidity and overall and disease-specific survival).
4. To assess the utility and uptake of the DESIs from 
the perspective of both clinicians and patients by 
undertaking a formal process evaluation.
Hypotheses
1. Use of the DESIs will improve the QoL in older women 
with operable breast cancer and ultimately improve 
cancer outcomes.
2. Older women faced with a choice of treatment 
decisions for their breast cancer will report an 
improved decision quality and shared decision-
making experience and less decision regret using 
DESIs compared with older women who receive usual 
clinical decision-making support.
3. Use of evidence-based DESIs will improve short 
and longer term outcomes by improving treatment 
personalisation to a woman’s health, fitness and 
cancer characteristics and by improving the quality 
of decision making, and reduce the heterogeneity of 
practice across the UK.
4. Women in the intervention sites will express more 
positive illness representations (eg, increased 
personal control, positive emotional consequences, 
less overall threat) and increased use of engagement 
coping strategies compared with women from the 
control sites.
Figure 1 Overview of the cluster randomised controlled trial. PET, primary endocrine therapy.
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METHODS
Study design and setting
This protocol follows the CONSORT (Consolidated 
Standards of Reporting Trials) statement guidelines for 
cluster trials.28
This study is a multicentre, parallel group, pragmatic 
cluster RCT (2015-18).29 It is nested within a larger 
ongoing Bridging the Age Gap cohort study (2012-18)21 
(figure 1) which is currently recruiting from 53 breast 
units within in the UK (observational cohort study of 
current UK management of older women with early 
breast cancer).
the rCt study
The intervention comprises implementation of a package 
of two DESIs for the PET versus surgery/AET, or chemo-
therapy versus no chemotherapy decisions. Each DESI 
includes an online algorithm for treatment outcomes, and 
two PtDAs—a booklet and a brief option grid.26 27 Each 
DESI is a complex intervention, including training for 
the clinician (breast surgeon, medical oncologist, breast 
care nurses) on the use of the algorithm (surgeons and 
medical oncologists only) or PtDAs, and the clinician and 
patient decide which, if any, of these elements they wish 
to use to assist the decision-making process, the intention 
being for the intervention to be used as part of everyday 
clinical practice/pathway within the intervention sites.
Each online algorithm includes functionality to adjust 
outcome prediction according to patient age, comor-
bidity, frailty, tumour stage and ER status and which gives 
outputs of 2 and 5-year overall and breast cancer specific 
survival. The algorithms were developed in the earlier 
phase of the Age Gap study25 and were designed to guide 
clinicians and their patients in the treatment of:
1. frailer older women with ER-positive breast cancer to 
optimise treatment with either PET or surgery/AET;
2. fitter older women who have already had primary 
surgery and been found to have high-risk cancer 
characteristics (eg, ER-negative, HER2-positive or 
node-positive breast cancer) to optimise treatment 
with either adjuvant chemotherapy or no adjuvant 
chemotherapy (note the term chemotherapy includes 
chemotherapy +/− trastuzumab if appropriate).
The algorithm is based on a computer model of predicted 
outcomes and variance caused by patient and disease 
parameters. Unlike existing web-based algorithms for 
cancer treatment (Adjuvant!OnLine19 or PREDICT20) 
which do not have the facility to specify frailty or comor-
bidity in detail (or at all), the Age Gap algorithm permits 
these factors to be taken into account. The Age Gap tool 
has been optimised for accuracy in this age group and 
has been based on analysis of data from over 20 000 UK 
women over the age of 70 derived from cancer registry 
data. The algorithm has built-in educational materials 
(including several online presentations, data sources, 
FAQs and an animated educational video). The online 
algorithm is designed to be used by clinicians to guide 
treatment decision making and its outputs can be printed 
off in a patient-facing format that could be used in 
personalised patient counselling. The report provides 
specific survival estimates for each treatment option for 
an individual woman based on her personal and cancer 
characteristics. This works in much the same way as the 
printouts from Adjuvant!Online19 or PREDICT20 but in 
this case developed for the PET versus surgery/AET deci-
sion and with more detailed data entry relating to the 
woman’s age and fitness level.
Two PtDAs (PET vs surgery/AET26 and chemotherapy 
vs no chemotherapy27) have been developed during 
the earlier phase of the study.22–24 The PtDAs comprise 
an option grid30 and a booklet for each decision. The 
option grid is a one-page evidence-based summary of 
the treatment options alongside patients’ frequently 
asked questions, helping patients to differentiate the key 
features, risks and benefits of treatment options in rela-
tion to their personal values and preferences. The option 
grid has been designed to be sufficiently brief for use in 
clinical encounters and accessible enough to support a 
better dialogue between patients and their clinical team.30 
The booklet provides information about both options 
including diagrams, side effects and potential risks and 
benefits. It also includes a section to guide deliberation 
and encourage the patients to clarify their preferences 
based around identifying ‘what is most important to 
them.’16
Eligibility criteria
Inclusion criteria
1. female;
2. aged over 70 years at the time of diagnosis of cancer;
3. primary operable (tumour, node, metastasis 
(TNM) categories V7: T1, T2, T3, N0, N1, M0), 
ER-positive invasive breast cancer (core biopsy or 
diagnostic incision biopsy);
4. ability to give informed consent and to read English.
Exclusion criteria
1. disease unsuitable for surgery, for example, 
inoperable, locally recurrent or metastatic disease;
2. previous invasive breast cancer within the last 5 years;
3. non-English speakers.
Data collection and outcomes
Primary outcome measure
The primary outcome measure for the RCT is global 
health status/QoL score (questions 29+30 only of The 
European Organization for Research and Treatment 
of Cancer QLQ-C30 Reference Manual) (EORTC 
QLQ-C30).31 This primary endpoint was stipulated by 
the funder of the study with the justification being that 
the EORTC QLQ-C30 is internationally recognised and 
well-validated QoL measure (as opposed to our original 
primary endpoint of decision quality). This was measured 
at 6 weeks and 6 months postdiagnosis/consent.
An independent data monitoring committee (DMC) 
comprising three experienced academic clinicians 
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oversees the study and monitors trial conduct and safety 
and potential harm and has access to all study data; the 
role being to provide recommendations for trial changes 
(or closure). Data collection is being undertaken by 
trained clinical staff within each of the participating 
sites. The study data manager and study monitor also 
undertake regular site visits to outline the study protocol, 
ensure protocol adherence and monitor data collec-
tion and completeness. Data collection for the study 
includes detailed information about the patients and 
their cancer at the time of diagnosis: age, comorbidity 
(Charlson comorbidity index,32 frailty—The Barthel 
Index (ADL, activities of daily living)33 and instrumental 
activities of daily living scores (IADL)34), cognitive 
status (Mini-Mental State Examination),35 baseline QoL 
(EORTC QLQ C30,31 EORTC breast cancer-specific QoL 
questionnaire (QLQ-BR23),36 EORTC QoL questionnaire 
module for older people with cancer (QLQ-ELD14),37 
EuroQol Group EQ-5D38), tumour stage, grade and 
receptor status. Treatment details are recorded including 
the type of surgery to the breast and axilla, use of adjuvant 
therapies (chemotherapy, radiotherapy, trastuzumab and 
hormonal therapies), including doses and adverse effects 
recorded using the Common Terminology Criteria for 
Adverse Events grading system. Follow-up is at baseline, 
6 weeks, and 6, 12, 18 and 24 months after diagnosis/
consent. Cancer outcomes, QoL and adverse events are 
recorded at each visit and in the longer term, women 
are asked to sign a consent form to permit the trial to 
collect their Cancer Registry data which will be collected 
5 and 10 years following diagnosis and consent to the 
study. These data will permit us to look at whether using 
the DESIs alters patterns of treatment decision making 
between control and intervention sites and whether these 
impact on long-term outcomes. As such this is a uniquely 
detailed evaluation of such DESIs.
In addition, specific questionnaires relating to patient 
choice and decision making will be administered. These 
will apply to all women offered a choice of either PET and 
surgery/AET or chemotherapy versus no chemotherapy 
and are administered in relation to the time of their 
treatment choice. Secondary outcome measures here 
include decision regret (Decision Regret Scale,39 shared 
decision making (CollaboRATE40), patient anxiety 
(Spielberger short-form state scale of the State-Trait 
Anxiety Inventory,41 knowledge and preference (knowl-
edge, readiness to decide and preference measure42 43), 
illness perceptions (Brief Illness Perceptions Question-
naire44) and Coping (brief COPE, Coping Orientation 
to Problems Experienced)45). Original data collected 
are entered and kept on file within each of the study 
sites. These data are entered electronically and stored 
securely onto password-protected databases within 
local databases and the main trial office. All records 
that contain names or other personal identifiers, such 
as locator forms and informed consent forms, are 
stored separately from study records identified by code 
number. Only the study steering and DMC have access 
to the full trial data set. Errors, discrepancies or missing 
data are captured by the computer programme and the 
study data manager checks and subsequently follows 
this up with participating sites.
The timescales for each of these are shown in table 1.
sample size calculation
The primary endpoint will be the global health status/QoL 
scale (questions 29 and 30 of the EORTC-QLQ-C30)31 at 
6 months post baseline. Assuming an SD of 21 points for 
the global health status/QoL scale and a mean difference 
of 7 or more points on the global health status/QoL scale 
between the groups is of clinical/practical importance (a 
‘small’ standardised effect size of 0.33). With no allowance 
for clustering; for the PET versus surgery DESI compar-
ison with 190 eligible women per group we will have a 90% 
power of detecting this difference or more as statistically 
significant between the groups at the 5% two-sided level. If 
we assume an intraclass correlation of 0.03 then allowing for 
the clustered RCT design we will need to recruit 10 women, 
eligible for using the decision aids, per cluster (ie, 50 clus-
ters × 10 women), 500 in total (this assumes a design effect 
of 1.3). With a 20% loss to follow-up by 6 months we need 
to recruit 13 women per cluster (50 clusters × 13 women) or 
650 in total (325 per group).
randomisation
Randomisation is at breast unit level, stratified by high 
and low PET and chemotherapy rates. It was therefore 
not possible to blind the investigators or the study sites 
to the allocation of participants. Data for this stratifi-
cation have been derived from the wider cohort study 
which has collected data on treatment rates for both 
PET versus surgery/AET and chemotherapy versus no 
chemotherapy.
Control arm
Usual standard practice for older women (>70 years) 
diagnosed with breast cancer with no change to normal 
treatment decision-making practice.
Intervention arm
Usual standard practice for older women (>70 years) 
diagnosed with breast cancer plus optional clinician and 
patient access to the package of DESIs which will have 
been made available to these units to adopt as their stan-
dard of care.
In the run into the trial period (June–December 2015), 
clinical teams (clinicians, research and breast nurses) 
from the participating sites attended a training event to 
enhance concordance with the study protocol (control 
group) and provide additional training on shared deci-
sion making and the use of the DESIs (intervention 
group). This comprised a 2-hour practical workshop 
which consisted of presentations, demonstrations and 
discussion based on the MAGIC programme.46
recruitment
Potentially eligible women are identified by clinicians 
(breast surgeons, medical oncologists and specialist 
breast nurses) and research nursing staff within 
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multidisciplinary teams of the study sites. Study packs 
are being given to eligible patients either following 
their clinical consultation where either PET or surgery/
AET options or chemotherapy versus no chemotherapy 
options are discussed. Monthly study newsletters are 
sent to all participating sites to provide feedback to staff 
in order to maintain interest and recruitment to the 
study. Any modifications to the original study protocol 
will be discussed with the data monitoring and ethics 
committee and approvals sought from the funder and 
the ethics committee. Recruitment for the trial has now 
commenced and 750 women have been recruited over 
the 53 participating sites.
data analysis
The statistical analyses will be performed on an intention-
to-treat basis comparing the DESI and control groups. All 
statistical exploratory tests will be two tailed with p=0.05. 
Baseline demographics (eg, age), physical measure-
ments and health-related QoL data will be assessed for 
comparability between the treatment groups. A marginal 
generalised linear model (GLM), with coefficients esti-
mated using generalised estimating equations (GEE) with 
robust SEs and an exchangeable autocorrelation matrix 
in STATA will be used to analyse the outcomes and allow 
for the clustered nature of the data. The exchangeable 
correlation structure corresponds to an equal correlation 
Table 1 Questionnaire schedule
Standard age gap 
questionnaires Baseline 6 weeks 6 months 12 months 18/24 months Long term
IADL *
ADL *
MMSE *
ECOG performance status *
Subjective global assessment *
Comorbidity *
EQ5D * * * * *
QoL (EORTC-QLQ C30, QLQ-
BR23 and QLQ-ELD14)
* * * * *
Decision quality * *
RECIST if PET * * * * *
Registry data access *
Tissue access * *
Tumour details *
Treatment details * * * * *
Adverse events * * * * *
New for DESI study  (if offered 
choice of either pet   or surgery/
AET, or chemotherapy/no 
chemotherapy)
Baseline (after consent for 
PET or surgery) (AET or after 
consultation for chemo/no 
chemo, as applicable)
6 weeks after 
relevant 
treatment 
choice
6 months 
after relevant 
treatment 
choice
Spielberger anxiety * *
Collaborate *
Decision regret * *
Knowledge readiness to decide and 
preference measures
*
Brief IPQ * *
Brief COPE * *
Process evaluation (if taking part in 
process evaluation)
Process evaluation questionnaire *
*indicated that these data are collected at this time point.
ADL, activities of daily living; AET, antioestrogen therapy; COPE, Coping Orientation to Problems Experienced; DESI, decision support 
intervention; ECOG, Eastern Cooperative Oncology Group; IADL, instrumental activities of daily living; IPQ, Illness Perception Questionnaire; 
MMSE, Mini-Mental State Examination; PET, primary endocrine therapy; QoL, quality of life; RECIST, Response Evaluation Criteria In Solid 
Tumors.
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model, meaning that the correlations of the outcomes with 
a cluster, that is, breast centres, are the same. For contin-
uous outcomes, such as mean global health status/QoL 
score (questions 29+30 of EORTC QLQ-C3031) at 6 months 
postdiagnosis/consent intervention, knowledge score and 
preference for treatment score, an identity link with a 
normal distribution for the outcome will be used. Estimates 
for the treatment group coefficient from this regression 
model will be reported along with their associated 95% 
CI. In the event of differences between the intervention 
and control groups with respect to baseline demographic, 
physical and health-related QoL measurements, then these 
covariates will be used in the GLM to adjust the treatment 
effect for these variables. The adjusted regression coeffi-
cient estimate for the treatment group parameter along 
with its 95% CI will then be reported.
For the other secondary outcomes, at 6 weeks and 6 
months, such as the other dimensions of the EORTC 
QLQ C30,31 the EORTC QLQ-BR2336 and EORTC 
QLQ-ELD14,37 the mean QoL dimension scores will be 
compared between the intervention and control groups 
using similar models.
A series of exploratory subgroup analyses using a 
marginal GLM with coefficients estimated using GEE with 
robust SEs and an exchangeable autocorrelation matrix, 
with the primary outcome the mean global health status/
QoL score (questions 29+30 of EORTC QLQ-C3031) at 
6-month postdiagnosis/consent randomisation as the 
response will be carried out. An interaction statistical 
test between the randomised intervention group and 
subgroup to directly examine the strength of evidence for 
the treatment difference between the treatment groups 
(intervention vs control) varying between subgroups will 
be undertaken. Age subgroup (75–79, 80–84, 85–89 and 
90+ years) and comorbidity levels (based on the modified 
Charlson comorbidity score32) will be the only a priori 
defined subgroups to be considered for interaction test. 
Subgroup analysis will be performed regardless of the 
statistical significance on the overall intervention effect 
(intervention vs control).
Missing primary outcome data
A sensitivity analysis using a variety of imputation methods 
to impute any missing primary outcome data (6-month 
EORTC QLQ-C3031 global health status/QoL score) will 
be performed. The imputation methods will include last 
observation carried forward, regression and multiple 
imputation. The estimates of the treatment effect and 
its associated CI, from the various imputation methods, 
will be graphically displayed alongside the results for the 
observed data.
Process evaluation
Running alongside the main study, a detailed mixed 
methods process evaluation is being undertaken at 16 
sites to assess the implementation of the DESIs (fidelity to 
the trial protocol) to consider the DESIs’ usefulness and 
acceptability and examine the facilitators and barriers 
to embedding them into everyday clinical practice. A 
random selection of breast units was made stratified by 
trial arm and recruitment rate to the cohort study (high/
low PET/surgery/chemo rates).
In summary, the Age Gap study21 aims at improving 
outcomes of older women diagnosed with breast cancer 
by providing high-quality evidence to support treatment 
decision making in this age group. The two evidence-
based DESIs each include a clinical management 
algorithm and two PtDAs in the form of a booklet and a 
(brief) option grid for the clinical decision in question. 
These online algorithms will allow patient age, comorbid-
ities, frailty and cancer characteristics to be considered 
by a clinician in predicting survival and cancer outcomes 
and to help inform breast cancer management decisions 
for older women.
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